Nair Prakash N, McArdle Linda, Cornell John, Cohn Susan L, Stallings Raymond L
Children's Cancer Research Institute and Department of Pediatrics, University of Texas Health Science Center at San Antonio, 8403 Floyd Curl Drive, Mail Code 7784, San Antonio, TX 78229, USA.
Cancer Genet Cytogenet. 2007 Apr 15;174(2):100-10. doi: 10.1016/j.cancergencyto.2006.11.017.
Large-scale hemizygous loss of chromosome 3p is a common event in neuroblastoma, occurring preferentially in tumors that exhibit loss of chromosome 11q and lack MYCN amplification. Although numerous tumor suppressor genes (TSG) have been mapped to the 3p region, the gene or genes contributing to neuroblastoma pathogenesis have remained elusive. High-resolution oligonucleotide array CGH mapping of chromosome 3p breakpoints relative to the positions of known TSGs indicates that more than one gene may contribute to neuroblastoma pathogenesis. We evaluated the methylation status of semaphorin 3B (SEMA3B), one of the chromosome 3p TSGs, in neuroblastoma tumors with (n = 12) and without (n = 32) 3p deletions. A significantly higher percentage of methylated CpG sites in the SEMA3B promoter was detected in tumors exhibiting 3p loss (95%), relative to tumors without loss (52%), suggestive of a two-hit mechanism of allele inactivation. The involvement of methylation in the control of SEMA3B expression was confirmed by treatment of neuroblastoma cell lines with the demethylating agent 5-aza-2-deoxycytidine. Transcriptional regulation of this locus is complex, however; low levels of SEMA3B expression were also seen in tumors with unmethylated SEMA3B promoters (n = 4). SEMA3B is known to play an important role in the development of normal sympathetic neurons, and interestingly, we found higher levels of SEMA3B expression in differentiated tumors with favorable histopathology (n = 19) than in tumors with unfavorable histology (n = 22). Furthermore, SEMA3B was upregulated in the SK-N-BE neuroblastoma cell line following induction of differentiation with retinoic acid. The association of SEMA3B expression with neuroblastoma differentiation suggests that this TSG may play a role in neuroblastoma pathobiology.
3号染色体短臂的大规模半合子缺失是神经母细胞瘤中的常见事件,优先发生于表现出11号染色体长臂缺失且缺乏MYCN扩增的肿瘤中。尽管众多肿瘤抑制基因(TSG)已被定位到3p区域,但导致神经母细胞瘤发病机制的一个或多个基因仍不明确。相对于已知TSG的位置,对3号染色体短臂断点进行的高分辨率寡核苷酸阵列比较基因组杂交图谱分析表明,可能不止一个基因参与神经母细胞瘤的发病机制。我们评估了神经母细胞瘤肿瘤中3号染色体短臂TSG之一的信号素3B(SEMA3B)的甲基化状态,其中有3p缺失的肿瘤12例,无3p缺失的肿瘤32例。相对于无3p缺失的肿瘤(52%),在表现出3p缺失的肿瘤(95%)中检测到SEMA3B启动子中甲基化CpG位点的比例显著更高,提示存在等位基因失活的双打击机制。用去甲基化剂5-氮杂-2'-脱氧胞苷处理神经母细胞瘤细胞系,证实了甲基化参与SEMA3B表达的调控。然而,该基因座的转录调控很复杂;在SEMA3B启动子未甲基化的肿瘤(n = 4)中也观察到低水平的SEMA3B表达。已知SEMA3B在正常交感神经元的发育中起重要作用,有趣的是,我们发现组织病理学良好的分化型肿瘤(n = 19)中SEMA3B的表达水平高于组织学不良的肿瘤(n = 22)。此外,在用视黄酸诱导分化后,SK-N-BE神经母细胞瘤细胞系中SEMA3B上调。SEMA3B表达与神经母细胞瘤分化的关联表明,该TSG可能在神经母细胞瘤病理生物学中起作用。